
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
A detailed drug history is essentialwhen treating patients with myastheniagravis-especially those whoreport a sudden increase in symptoms.
A detailed drug history is essentialwhen treating patients with myastheniagravis--especially those whoreport a sudden increase in symptoms.Commonly prescribed medicationssuch as aminoglycosides (eg,gentamicin), lithium, phenytoin,procainamide, quinidine sulfate, andβ-adrenergic blockers (includingeyedrops) can exacerbate muscularweakness in myasthenia gravis.
-- Sonia Arunabh, MD
K. Rauhilla, MD
New Hyde Park, NY






